Driven by Industry Demand, Georgia Bio Reemerges, Rededicates

Georgia Bio logo with tagline

A New Start

Founded in 1989, Georgia Bio has been the entity around which the bioscience and medtech industry in the state, including academia, connects and advocates for its needs.

Though recently latent in the visual presence to which stakeholders are accustomed, Georgia Bio has maintained, if not increased, its advocacy for the life science industry at the state level. Over the past two years, Georgia Bio operated under the moniker “Office of Life Sciences and Digital Health” within the Center for Global Health Innovation (CGHI). Given CGHI’s changing scope, Georgia Bio reemerges as a 501c6 trade organization serving its member stakeholders directly inclusive of advocacy and lobbying activities. Georgia Bio has finalized the steps needed to regain its full autonomy and independence from CGHI.

“The ‘re-emergence’ of Georgia Bio is an industry demand-driven development,” Georgia Bio CEO Maria Thacker says. “Academic and industry life science leaders have told us directly that they need a strong advocacy organization around which to engage with each other and advance their priorities. Those industry leaders are also prepared to provide the financial support required for Georgia Bio to be the entity that provides those services.”

Not Just Pharma: A Holistic View of the Life Sciences

Known most for its focus in the biotech and pharmaceutical sectors of the life sciences, Georgia Bio intends to bring the breadth of the life science innovation ecosystem into its “family” inclusive of medical devices, food and agricultural technology and the solutions providers that support them. The increasing number of ‘combination devices,’ medical technologies that are part drug, part device in simplest terms, is one of the easiest ways to understand why the expansion of focus is needed. The affiliated solution providers on which the entire industry relies, including intellectual property experts, contract manufacturers and proving grounds like the Global Center for Medical Innovation is another.

“Ultimately, we intend to foster innovation and growth of Georgia’s life science ecosystem for a healthier world,” Thacker says. “We will advocate for, connect, educate and inspire our member enterprises and stakeholders in much the same way our colleagues have known Georgia Bio since its inception in 1989. We will now do that through an industry-wide lens including new medical technologies and devices.”

Supporting an Industry with $50 Billion Impact and High Workforce Development Needs

A top priority for the organization in addition to advocacy will be continued strengthening of its workforce development programming.

The 2022 Georgia Life Sciences Industry Trends and Impacts Report states, “Job growth in the industry has been driven primarily by the industrial life sciences segment which has increased by nearly 29% and outpaced the nation, while the academic and federal R&D component has experienced more modest growth. In 2021, Georgia’s life sciences industry and its multiplier effects generated: a total employment impact of nearly 215,000 Georgia workers across all sectors, a combined $50.2 billion in total economic impact to Georgia’s economy, and a total value added impact of $26.7 billion to Georgia’s GSP-representing 3.9% of state GSP.”

The growth of the sector across the state has also increased the need for a skilled workforce to support it. In that regard, the Georgia BioEd Institute will serve as the 501c3 public service entity whose education and workforce development endeavors will be administered by the Georgia Bio team as well. The Institute will operate inside of Georgia Bio with the 501c3 status anticipated to be completed by early 2024.

The 2023 Georgia Life Science Summit

Coming out swinging, Georgia Bio hosted The Georgia Life Science Summit on November 1, 2023 at the Sandy Springs Arts Center.

“The Summit was more concentrated in its focus, yet more expansive in its industry-wide inclusion, compared to previous editions of our Bio Innovation Summit,” Thacker says. “In line with what the industry has told us it wants and needs, the event will bring together roughly 300 academic and industry leaders to connect, learn, share and network.”

For more information, visit www.georgiabiosummit.org.

About Georgia Bio

Georgia Bio represents more than 200 organizations in the life sciences industry, including biopharma, medical device, combination product and digital health companies, along with academic institutions, research hospitals, disease foundations and solutions providers on which those entities rely. www.gabio.org

____________________________________________________________________

Biotech Leaders Launch National Alliance to Define the Future of American Innovation

May 5, 2026
New coalition forms to develop a national innovation roadmap to strengthen and extend  America’s global leadership in biotechnology

UGA & Manus Among Awardees in $214M BioMADE Investment

April 30, 2026
BioMADE Announces $21.4 Million Invested in 14 Projects to Develop the U.S. Bioindustrial Manufacturing Industry and Advance National Security Priorities

Nutrivert announces first close on $6 million Series A-2 funding round

April 17, 2026
April 17, 2026 - Nutrivert Inc., a developer of non-antibiotic replacements for antibiotic growth promoters in livestock, today announced it has completed the first close, raising $2.375 million, of its Series A-2 funding round of $6 million. The round was led by global animal health investor Arrow Ventures with participation from other investors. The funding will be used to further develop Nutrivert’s manufacturing, human food safety and target animal safety and efficacy packages for the company’s lead product Nutrivert LDPP. Nutrivert LDPP is a proprietary, novel, orally available, lipidated synthetic enantiomeric desmuramyl analog of muramyl dipeptide, the smallest conserved immunoactive component of bacterial peptidoglycan. LDPP has no antibacterial effect but has consistently promoted growth and improved feed efficiency in pig studies. LDPP binds to the mammalian NOD2 receptor and is the only NOD2 ligand reported to inhibit the inflammatory signal NF-κB. In pilot studies, LDPP rescued 70kg pigs from an otherwise lethal dose of porcine reproductive and respiratory syndrome virus (PRRSV) and abrogated influenza disease symptoms in piglets. The Company intends to develop LDPP for all major livestock species worldwide. Patents have been granted in most major markets. The global antibiotic growth promoter market is worth an estimated $5.8 billion. Approximately 73% of all antibiotics are fed to livestock. The market is believed to be the world’s largest drug market by volume, with ~100,000 tons of active pharmaceutical ingredient administered annually. FDA’s latest data, for 2024, show a 13% rise in U.S. livestock antibiotic use since 2017. The Food and Agriculture Organization reports that livestock antibiotics are mostly given to speed animal growth. Regulators and non-governmental organizations have called for reduction of antibiotic use in livestock, citing concerns that the global, intensive use of antibiotics, often at subtherapeutic doses, selects for antimicrobial resistance: bacteria that are “immune” to antibiotics and that therefore pose a threat to public health. Spillovers of antibiotic-resistant bacteria from livestock to humans have been documented. “Nutrivert LDPP has consistently improved feed efficiency in pigs without antibiotics,” said Bernhard Kaltenboeck, CSO. “We are excited to have the support of Arrow Ventures and our other investors in bringing a new tool that will help producers reduce production costs and reduce selection pressure for antimicrobial resistance.” About Nutrivert LDPP: LDPP is an investigational compound currently undergoing clinical evaluation. It has not been approved by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or any other global regulatory authority for any indication. The safety and efficacy of LDPP have not been established. Any mention of potential use is based on preliminary data and does not guarantee future regulatory clearance or commercial availability.
MORE POSTS